COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Comparison Between Raloxifene and Bazedoxifene

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01973738
Recruitment Status : Unknown
Verified October 2016 by Toshihiko Kono, Tomidahama Hospital.
Recruitment status was:  Recruiting
First Posted : October 31, 2013
Last Update Posted : October 19, 2016
Information provided by (Responsible Party):
Toshihiko Kono, Tomidahama Hospital

Brief Summary:
Although there are two kinds of selective estrogen receptor modulator (SERM) :raloxifene (RLX) and bazedoxifene (BZA), the difference is still unclear. In this study, we plan to compare clinical efficacy and safety between RLX and BZA.

Condition or disease
Selective Estrogen Receptor Modulator

Detailed Description:

Selective estrogen receptor modulator (SERM) is an important option for postmenopausal osteoporosis. There are two SERM approved in Japan for the treatment of postmenopausal osteoporosis in women at increased risk of fracture. One is raloxifene (RLX), and the other is bazedoxifene (BZA). There are few reports concerning to the clinical efficacy and safety data. In this study, we plan to compare clinical efficacy and safety between RLX and BZA.

The main objective of this study is to reveal the effects of RLX and BZA on bone mineral density, bone turnover markers, and bone quality markers.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 300 participants
Observational Model: Case Control
Time Perspective: Prospective
Official Title: Comparison of the Clinical Efficacy and Safety Between Raloxifene and Bazedoxifene in Postmenopausal Women.
Study Start Date : January 2012
Estimated Primary Completion Date : December 2017
Estimated Study Completion Date : December 2018

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. Effects of raloxifene vs. bazedoxifene on bone mineral density, bone turnover markers and bone quality markers in postmenopausal osteoporosis. [ Time Frame: Up to 72 months ]

    The investigators plan to analyze 300 patients who undergo selective estrogen receptor modulator (SERM) treatments for five years.

    We investigate the efficacy of two SERMs: raloxifene (RLX) and bazedoxifene (BZA). Bone mineral density (BMD) andd laboratory analyses (bone markers, routine chemistry, urine, and bone quality marker of pentosidine) at baseline and every four to six months. We also investigate the side effects. Statical analyses are performed using Spearman correlation coefficients, paired t-test, Mann-Whitney U test, chi-square test and Fisher's exact test to compare the efficacy and safy between RLX and BZA.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   45 Years to 100 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Osteoporosis patients using SERM more for five years.

Inclusion Criteria:

  • Postmenopausal women

Exclusion Criteria:

  • Patients who could not use SERM

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01973738

Layout table for location information
Tomidahama Hospital Recruiting
Yokkaichi, Mie, Japan, 510-8008
Contact: Rui Niimi, MD, PhD    (81)-59-365-0023   
Sponsors and Collaborators
Toshihiko Kono
Layout table for additonal information
Responsible Party: Toshihiko Kono, Head of Hospital, Tomidahama Hospital Identifier: NCT01973738    
Other Study ID Numbers: IRB TH 05
First Posted: October 31, 2013    Key Record Dates
Last Update Posted: October 19, 2016
Last Verified: October 2016
Keywords provided by Toshihiko Kono, Tomidahama Hospital:
bone mineral density
bone turnover markers
bone quality